The synergy between alkylating agents and ERCC1-XPF inhibitors is p53 dependent.

Ciniero G, Pedro TM, Dumontet C, Elmenoufy AH, West FG, Weinfeld M, Gentile F, Tuszynski JA, Cros-Perrial E, Jordheim LP

Open source

DOI
10.1111/fcp.13043
Published
2025 Feb
Container
Fundamental & clinical pharmacology
Publisher
Not recorded
Open access
unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1111/fcp.13043,
  title = {The synergy between alkylating agents and ERCC1-XPF inhibitors is p53 dependent.},
  author = {Ciniero G and Pedro TM and Dumontet C and Elmenoufy AH and West FG and Weinfeld M and Gentile F and Tuszynski JA and Cros-Perrial E and Jordheim LP},
  year = {2025},
  journal = {Fundamental \& clinical pharmacology},
  doi = {10.1111/fcp.13043},
  url = {https://doi.org/10.1111/fcp.13043}
}

RIS

TY  - JOUR
TI  - The synergy between alkylating agents and ERCC1-XPF inhibitors is p53 dependent.
AU  - Ciniero G
AU  - Pedro TM
AU  - Dumontet C
AU  - Elmenoufy AH
AU  - West FG
AU  - Weinfeld M
AU  - Gentile F
AU  - Tuszynski JA
AU  - Cros-Perrial E
AU  - Jordheim LP
PY  - 2025
JO  - Fundamental & clinical pharmacology
DO  - 10.1111/fcp.13043
UR  - https://doi.org/10.1111/fcp.13043
ER  - 

APA

G, C., TM, P., C, D., AH, E., FG, W., M, W., F, G., JA, T., E, C., & LP, J. (2025). The synergy between alkylating agents and ERCC1-XPF inhibitors is p53 dependent.. Fundamental & clinical pharmacology. https://doi.org/10.1111/fcp.13043

Source records